◈ Nootpedia
Compact view
Research pass: medium AAS · Oil injectable SKIP-PERMANENT HIGH

Trestolone

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-PERMANENT HIGH

Severe HPG-axis shutdown in a developing 20yo endocrine system + WADA-banned + gray-market only + zero brain-priority benefit + Population Council designed it specifically AS a male contraceptive (the suppression is the desired clinical effect). No pathway to "yes" for Dylan.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-PERMANENT

    Severe HPG-axis suppression in developing endocrine system. Zero brain benefit. WADA-banned (irrelevant for Dylan but signals risk profile). Gray-market only. The compound was DESIGNED as a contraceptive — that mechanism is the dealbreaker, not a side effect.

  • 30-50, executive maintenance
    SKIP

    No use case. TRT with testosterone is the legitimate path if hypogonadal, with bloodwork-guided protocol.

  • 50+, mild cognitive decline
    SKIP

    No relevance.

  • Anxiety-prone
    SKIP

    AAS-class mood lability is contraindicated.

  • High athletic load, tested status
    SKIP

    WADA S1 banned.

  • Sleep-disordered
    SKIP

    Worsens sleep.

  • Recovery-focused (post-injury, post-illness)
    SKIP

    Other anabolics (testosterone TRT under physician care) have established protocols and don't carry MENT's full-shutdown profile.

  • Strength/anabolic-focused
    CONDITIONAL

    adult males 30+, post-bloodwork, off-cycle bodybuilders willing to do full PCT. Even here, testosterone enanthate is the safer first-AAS choice. MENT is for experienced users with a specific lean-recomp goal.

▸ Subjective experience (deep)

Per user reports (NOT Dylan-applicable, contextual only):

  • Onset: Days (acetate ester) to 1-2 weeks (enanthate)
  • Body comp: Aggressive lean mass + fat loss; "recomp" reports common
  • Libido: High initially, then crashes hard once endogenous T is shut down and E2 climbs
  • Mood: Lability, irritability, aggression at higher doses
  • Pumps: Strong; some report joint stiffness
  • Estrogenic sides: Bloat, gyno risk if AI not used (MENT aromatizes 4× more efficiently than testosterone)
  • Post-cycle: Severe — full HPG shutdown means crash of endogenous T after clearance, requiring SERM-based PCT (Nolva/Clomid) and often hCG mid-cycle
  • Users uniformly describe it as a "serious compound, not for beginners"
▸ Tolerance + cycling deep dive
  • Tolerance: Receptor desensitization not a major issue; suppression IS the dose-limiting factor
  • Recommended cycle (gray-market norm, NOT endorsed): 8-12 weeks max
  • Reset protocol: Full SERM PCT (Nolva 40/40/20/20 or Clomid 50/50/25/25), often with hCG run mid-cycle to preserve testicular function. Recovery time: 3-12 months. Some users never fully recover, especially if started young.
▸ Stacking deep dive

Synergistic with

  • N/A for Dylan — compound is skipped.

Avoid stacking with

  • Any other AAS — additive HPG suppression, additive lipid/cardiovascular damage
  • Other 19-nors (nandrolone, trenbolone) — overlapping PR binding, more progestogenic gyno risk
  • Oral 17α-alkylated AAS (oxandrolone, etc.) — additive lipid/hepatic stress

Neutral / safe co-administration

  • N/A — compound is skipped for Dylan.
▸ Drug interactions deep dive
  • CYP enzymes: Minor inducer at high doses; not clinically significant
  • Anticoagulants: AAS class effect — can potentiate warfarin; Dylan is not on AC
  • Insulin/oral hypoglycemics: AAS can worsen insulin sensitivity in some users; N/A for Dylan
  • Aromatase inhibitors (anastrozole, exemestane): Co-administration is standard practice when using MENT; AI is required to manage 7α-methylestradiol
▸ Pharmacogenomics
  • AR CAG repeat length: Shorter CAG = more sensitive AR = stronger anabolic AND side effect response. 23andMe will give Dylan rough indication; relevant if he ever revisits AAS class compounds at 30+.
  • CYP19A1 (aromatase) variants: Affect estrogen conversion rate; high-aromatizers see more E2 sides on MENT
  • APOE4: Lipid-mediated CV risk amplifier; relevant for any AAS class long-term
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Gray-market UGL Various $80-150/10 mL @ 50 mg/mL Variable, COA-dependent Trestolone acetate most common; trestolone enanthate less common, longer ester
Research chem Some vendors list as "research only" ~$100-200/g raw Low without testing Not pharma-grade, dosing unreliable
Pharmacy None N/A N/A Not approved anywhere as a marketed drug

Bottom line: No legitimate path. UGL only. COA verification mandatory if it were ever pursued.

▸ Biomarkers to track (deep)

(If ever used — not recommended for Dylan)

  • Baseline (before starting): LH, FSH, total T, free T, SHBG, estradiol (sensitive assay), full lipid panel, ALT, AST, GGT, hematocrit, hemoglobin, PSA, blood pressure, ECG
  • During use: Estradiol every 2-4 weeks (AI titration); lipids at week 4 and 8; hematocrit at week 6
  • Post-cycle: LH, FSH, total T at week 4 post, week 8 post, week 16 post until baseline recovery confirmed. If T not recovered by 6 months — endocrinology referral.
▸ Controversies / open debates Live debate
  • Is MENT safer than testosterone for TRT? Population Council research suggests yes (no DHT-driven prostate effects, single-compound replacement). Bodybuilding community disagrees — argues testosterone is more studied and reversible. Unresolved; not relevant for a 20yo.
  • PR binding clinical significance: Some sources call MENT "non-progestational"; others note enough PR activity to contribute to gyno risk. Probably dose-dependent.
  • HPG-axis recovery in young users: Limited data on under-25 users; precautionary principle says recovery risk is higher.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-PERMANENT. HPG-axis shutdown in 20yo developing endocrine system is a hard line. Zero brain benefit. Designed as a contraceptive — that's diagnostic. Compound is NOT in the consideration set for Dylan and won't be revisited until 30+ with full bloodwork history and a specific clinical or recomp goal that can't be met by safer alternatives.
▸ Open questions / gaps Open
  • Long-term cardiovascular outcomes data: thin, mostly inferred from 19-nor class
  • HPG-axis recovery rates in users <25: essentially no published data
  • AR CAG repeat × MENT response: theoretical, not directly studied
  • Whether MENT-only TRT becomes FDA-approved (Population Council program ongoing): would change adult-use calculus, not 20yo calculus
▸ Sources (full, with our context)
  • Population Council Male Contraceptive Program (multiple publications, 1995-2020) — primary source for human pharmacology
  • Anderson RA et al. — MENT acetate implant trials (J Clin Endocrinol Metab) — efficacy and HPG suppression data
  • Sundaram K, Kumar N, Bardin CW — original MENT pharmacology (Steroids journal, 1990s)
  • Meso-Rx, EliteFitness UGL community reports — anecdotal subjective + dosing norms (low-reliability tier)
  • WADA Prohibited List — confirms S1 anabolic agent classification
Back to compact view